Table 3.

The relationship between no. 12b, 13, and 14v LNs involvement and clinicopathological factors

Clinicopathological factors	No.12b		P value	No.13		P value	No.14v		P value
	+	−		+	−		+	−
T category			0.625			0.382			0.304
T1–2	0	6		0	6		0	6
T3–4	1	25		3	23		4	22
No. 6 LNs			0.340			0.087			0.045
Negative	0	15		0	15		0	15
Positive	1	16		3	14		4	13
Duodenum involvement			0.370			0.039			0.419
No	1	17		0	18		3	15
Yes	0	14		3	11		1	13
Tumor size			0.400			0.335			0.135
≥ 5 cm	0	13		2	11		3	10
< 5 cm	1	18		1	18		1	18
Histological type			0.723			0.827			0.884
Adenocarcinoma
Poorly	1	13		2	12		2	12
Well-moderately	0	14		1	13		2	12
SRCC	0	3		0	3		0	3
MAC	0	1		0	1		0	1
CA19-9 (U/ml)			0.625			0.382			0.732
≥ 37	0	6		0	6		1	5
< 37	1	25		3	23		3	23
CEA (ng/ml)			0.662			0.434			0.581
≥ 5	0	5		0	5		1	4
< 5	1	26		3	24		3	24
AFP (ng/ml)			0.744			0.558			0.492
≥ 10	0	3		0	3		0	3
< 10	1	28		3	26		4	25

SRCC signet ring cell carcinoma; MAC mucinous adenocarcinoma; CA19-9 carbohydrate antigen 19-9; CEA carcinoembryonic antigen